tirzepatide coming off FDA confirms shortage is still over, gives compounders a grace period Research finds that patients on

Per publicly available announcements, the FDA issued more than 50 warning letters to GLP-1 compounders and manufacturers in September 2025, followed by 30 additional warning letters to telehealth firms in early 2026, targeting false or misleading marketing claims about compounded GLP-1 products

Additionally, some patients experience dyspareunia (5) and dysmenorrhea (6)

If your lifestyle or labs suggest higher oxidative stress, a glutathione supplement can help

Prohibited Uses Our products are NOT approved for: Human consumption or administration Veterinary or animal use Diagnostic procedures Therapeutic applications Cosmetic application Resale for non-research purposes Buyer Responsibility By purchasing from Kinetic Compounds, you acknowledge and agree to the following: You are a qualified researcher or represent a research institution All products will be used solely for in-vitro laboratory research You will handle products in accordance with applicable safety regulations You will not redistribute these compounds for human or animal consumption You assume full responsibility for the proper use and handling of these research materials Related products Retatrutide Starter Kit 5.00 out of 5 SLU-PP-332 AOD-9604 5.00 out of 5 5-Amino-1MQ 5.00 out of 5 Tirzepatide 5.00 out of 5 Retatrutide 5.00 out of 5

Those statements can blur the line between laboratory material and patient treatment